Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20568457 | 1.00 | PDE5A (1.00) | PDE5AHDAC1HDAC2HDAC6 | |
| SCHEMBL20567813 | 0.97 | PDE5A (0.94) | PDE5A | |
| SCHEMBL22028314 | 0.97 | PDE5A (0.94) | PDE5A | |
| SCHEMBL31651388 | 0.97 | PDE5A (0.94) | PDE5A | |
| SCHEMBL20567814 | 0.97 | PDE5A (0.94) | PDE5A | |
| SCHEMBL31651393 | 0.92 | PDE5A (0.86) | PDE5A | |
| SCHEMBL22028317 | 0.92 | PDE5A (0.86) | PDE5A | |
| SCHEMBL22028296 | 0.92 | PDE5A (0.84) | PDE5AHDAC1HDAC2HDAC6 | |
| SCHEMBL22028295 | 0.92 | PDE5A (0.84) | PDE5AHDAC1HDAC2HDAC6 | |
| SCHEMBL20569321 | 0.91 | PDE5A (1.00) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4696376-A2 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | Topadur Pharma AG (CH) | 2026-02-18 | — | — | EP | claimed |
| EP-3630769-B1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2025-07-02 | — | — | EP | claimed |
| US-20240360136-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2024-10-31 | — | — | US | claimed |
| CN-118063458-A | Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-05-24 | — | — | CN | claimed |
| CN-110621676-B | Dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-02-09 | — | — | CN | claimed |
| US-20220073529-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-03-10 | — | — | US | claimed |
| US-11155558-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2021-10-26 | — | — | US | claimed |
| US-20200181149-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2020-06-11 | — | — | US | claimed |
| CN-110621676-A | Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2019-12-27 | — | — | CN | claimed |
| EP-4696376-A2 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | Topadur Pharma AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-3630769-B1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| US-20240360136-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2024-10-31 | — | — | US | disclosed |
| CN-118063458-A | Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11905293-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2024-02-20 | — | — | US | disclosed |
| CN-110621676-B | Dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20220073529-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-03-10 | — | — | US | disclosed |
| US-11155558-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2021-10-26 | — | — | US | disclosed |
| US-20200181149-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2020-06-11 | — | — | US | disclosed |
| CN-110621676-A | Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2019-12-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073529-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE1A, PDE2A | PDE5A 1/4885HDAC1 919/4885HDAC2 1160/4885 |
| US-11155558-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | PDE7A, GNAO1, PDE3A | PDE5A 11/4885HDAC1 1269/4885HDAC2 1688/4885 |
| US-20200181149-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, PDE3A, PDE9A | PDE5A 10/4885HDAC1 1204/4885HDAC2 1713/4885 |
| US-11905293-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | PDE5A, PDE1A, PDE2A | PDE5A 1/4885HDAC1 919/4885HDAC2 1160/4885 |
| US-20240360136-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE1A, PDE2A | PDE5A 1/4885HDAC1 919/4885HDAC2 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.